FindMyKOL

Vani Gandhi, MD

Basic profile

Icahn School of Medicine at Mount Sinai

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew York, NY · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLFindMyKOL type: RegionalLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Vani Gandhi is an Infectious Disease physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 11 publications with 296 citations (h-index 4).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
11publications

Publications indexed by OpenAlex. Counts exclude supporting files.

296citations

Citations across these publications.

4h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Gilead Sciences, Inc.
    Program year20253 payments
    $65
  • Gilead Sciences, Inc.
    Program year20241 payment
    $119
  • ViiV Healthcare Company
    Program year20211 payment
    $21

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    26.2%
    Statin7.7%
    Atorvastatin Calcium68%Pravastatin Sodium17%Rosuvastatin Calcium12%Livalo2%Lovastatin2%
    Part D<11 patients
    Calcium channel blocker5%
    Amlodipine Besylate73%Nifedipine Er24%Diltiazem 24hr Er (Cd)3%
    Part D<11 patients

    + 15 more classes in this area

  • Anti-infectives

    24.4%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor6.7%
    Tivicay44%Juluca37%Isentress11%Dovato8%
    Part D<11 patients
    Protease Inhibitor5.9%
    Prezcobix39%Ritonavir16%Evotaz14%Prezista11%Atazanavir Sulfate7%Darunavir6%Symtuza4%Lopinavir-Ritonavir3%
    Part D<11 patients

    + 12 more classes in this area

  • Nervous system

    14.1%
    Gabapentinoids3.3%
    Gabapentin85%Pregabalin15%
    Part D<11 patients
    Opioid Agonist2.7%
    Oxycodone Hcl35%Oxycodone-Acetaminophen30%Tramadol Hcl13%Methadone Hcl12%Endocet11%
    Part D<11 patients

    + 15 more classes in this area

Where care is delivered (Part B)82.1% facility · 17.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”